- Home
- RIGL vs SIBN Comparison
RIGL vs SIBN Comparison
Compare RIGL & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | SIBN |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 883.4M |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RIGL | SIBN |
|---|---|---|
| Price | $43.85 | $20.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.20 | $25.57 |
| AVG Volume (30 Days) | ★ 506.3K | 477.9K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | $193,578,000.00 |
| Revenue This Year | $65.53 | $21.44 |
| Revenue Next Year | $0.22 | $15.37 |
| P/E Ratio | $7.10 | ★ N/A |
| Revenue Growth | ★ 79.13 | 23.27 |
| 52 Week Low | $15.50 | $12.50 |
| 52 Week High | $52.24 | $21.07 |
Technical Indicators
Market Signals| Indicator | RIGL | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 64.54 |
| Support Level | $40.52 | $20.02 |
| Resistance Level | $44.85 | $21.07 |
| Average True Range (ATR) | 2.33 | 0.71 |
| MACD | -0.27 | 0.04 |
| Stochastic Oscillator | 51.26 | 76.74 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.